Abstract
The aims of this study were to compare the response to therapy in disease activity in pagetic patients with and without skull involvement and the usefulness of bone markers in the evaluation of these patients. Forty patients with Paget’s disease treated with tiludronate and 26 healthy controls were included. Serum total and bone alkaline phosphatases (TAP, BAP), procollagen I N propeptide (PINP), and urinary N- and C-terminal cross-linking telopeptides of collagen I (NTX, α-α CTX, and β-β CTX) were measured at baseline and 6 months after therapy. The extent of the disease was evaluated using the Coutris’ index. Pagetic patients were classified into three groups: patients with skull involvement (G-I, n = 12), patients without skull involvement (G-II, n = 28), and a subgroup of patients from G-II without skull involvement but with similar disease extent to G-I (G-III, n = 10). At baseline, patients from G-I showed significantly higher values in most markers compared to G-II. α-α CTX was the marker with the highest values in all groups. Moreover, monostotic patients with skull involvement showed higher serum baseline values of TAP per unit of affected area than monostotic patients without skull involvement. After therapy, the percentage of patients with markers within the normal range was lower in G-I than in G-II and G-III. In conclusion, pagetic patients with skull involvement showed a marked increase in bone turnover and a lower response to therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Selby PL, Davie MWJ, Ralston SH, Stone MD (2002) Guidelines on the management of Paget’s disease of bone. Bone 31:10–19
Siris E, Roodman G (2003) Paget’s disease of bone. In: Favus MJ (ed), Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism, 5th ed. American Society for Bone and Mineral Research, Washington DC, pp 495–506
Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J (2004) Long-term biochemical response after bisphosphonate therapy in Paget’s disease of bone. Proposed intervals for monitoring treatment. Rheumatology 43:869–874
Papapoulos SE, Frolich M (1996) Prediction of the outcome of treatment of Paget’s disease of bone with bisphosphonates from short-term changes in the rate of bone resorption. J Clin Endocrinol Metab 81:3993–3997
Patel S, Stone MD, Coupland C, Hosking DJ (1993) Determinants of remission of Paget’s disease of bone. J Bone Miner Res 8:1467–1473
Khan SA, Mc Closkey EV, Nakatsuka K, Orgee J, Coombes GM, Kanis JA (1996) Duration of response with oral clodronate in Paget’s disease of bone. Bone 18:185–190
Meunier PJ, Salson C, Mathieu L, Chapuy MC, Delmas P, Alexandre C, Charhon S (1987) Skeletal distribution and biochemical parameters of Paget’s disease. Clin Orthop Relat Res 217:37–44
Harnick HIJ, Bijvoet OLM, Vellenga CJLR, Blanksma HJ, Frijlink WB (1986) Relation between signs and symptoms in Paget’s disease of bone. QJM 58:133–151
Alvarez L, Peris P, Pons F, Guañabens N, Herranz R, Monegal A, Bedini JL, Deulofeu R, Martínez de Osaba MJ, Muñoz-Gómez J, Ballesta AM (1997) Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget’s disease activity. Arthritis Rheum 40:461–468
Smith SE, Murphey MD, Motamedi K, Mulligan ME, Resnik CS, Gannon FH (2002) Radiologic spectrum of Paget disease of bone and its complications with pathologic correlation. Radiographics 22:1191–1216
Alvarez L, Guañabens N, Peris P, Vidal S, Ros I, Monegal A, Bedini JL, Deulofeu R, Pons F, Muñoz-Gómez J, Ballesta AM (2001) Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget’s disease. Bone 29:447–452
Alexandersen P, Peris P, Guañabens N, Byrjalsen I, Alvarez L, Solberg H, Cloos PAC (2005) Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget’s disease of bone. J Bone Miner Res 20:588–595
Coutris G, Cayla J, Rondier J, Talbot JN, Bonvarlet JP, Milhaud G (1975) Analyse des perturbations des voies principales du metabolism calcique dans la maladie de Paget: effets de l’administration de calcitonine. Rev Rhum Mal Osteoartic 42:759–767
Allen MR, Hock JM, Burr DB (2004) Periosteum: biology, regulation, and response to osteoporosis therapies. Bone 35:1003–1012
Solchaga LA, Cassieda P, Caplan AI (1998) Different response to osteo-inductive agents in bone marrow- and periosteum-derived cell preparations. Acta Orthop Scand 69:426–432
Everts V, Korper W, Jansen C, Steinfort J, Lammerse I, Heera S, Docherty AJ, Beertsen W (1999) Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. FASEB J 13:1219–1230
Alvarez L, Ricos C, Peris P, Guañabens N, Monegal A, Pons F, Ballesta AM (2000) Components of biological variation of biochemical markers of bone turnover in Paget’s bone disease. Bone 26:571–576
Fledelius C, Johnsen AH, Cloos PAC, Bonde M, Qvist P (1997) Characterisation of urinary degradation products derived from type I collagen. J Biol Chem 272:9755–9763
Cloos PAC, Fledelius C (2000) Collagen fragments in urine derived from bone resorption are highly racemized and isomerized. A biological clock of protein ageing with clinical potential. Biochem J 345:473–480
Garnero P, Fledelius C, Gineyts E, Serre CM, Vignot E, Delmas PD (1997) Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget’s disease of bone. J Bone Miner Res 12:1407–1415
Garnero P, Gineyts E, Schaffer AV, Seamen J, Delmas PD (1998) Measurement of urinary excretion of nonisomerized and b-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget’s disease. Arthritis Rheum 41:354–360
Langton AL, Ralston SH (2004) Management of Paget’s disease of bone. Rheumatology 43:955–959
Guañabens N, Alvarez L, Cerdá D, Vidal S, Monegal A, Peris P, Ros I, Ballesta A, Pons F (2003) Similar effects of tiludronate and risedronate on Paget’s disease activity assessed by bone markers. J Bone Miner Res 18(suppl 2):S388–S389
Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 353:898–908
Donáth J, Krasznai M, Fornet B, Gergely P Jr, Poór G (2004) Effect of bisphosphonates treatment in patients with Paget’s disease of the skull. Rheumatology 43:89–94
Acknowledgments
The study was supported in part by a grant from the Instituto de Salud Carlos III C03/08. We are grateful to Llorenç Quintó for revising the statistical analysis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Peris, P., Alvarez, L., Vidal, S. et al. Biochemical Response to Bisphosphonate Therapy in Pagetic Patients with Skull Involvement. Calcif Tissue Int 79, 22–26 (2006). https://doi.org/10.1007/s00223-005-0247-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-005-0247-9